Get the latest delivered to your inbox
Privacy Policy

Now Reading

Impacting Human Health: Moderna’s 2021 ESG Report

Impacting Human Health: Moderna’s 2021 ESG Report

Published 06-24-22

Issued by Moderna


The past year was one of monumental impact and change for Moderna. In the fight against the pandemic, the Moderna team showed relentlessness under tight timelines and COVID-related challenges, while advancing its COVID-19 vaccine and broad pipeline of mRNA medicines, always with a deep sense of purpose and care for patients, employees, the environment, and the community. With the publication of its very first Environmental, Social and Governance Report, Moderna reflects on how the COVID-19 pandemic has exacerbated inequalities around the world, the urgent need to increase access to quality healthcare and medicines, to close the opportunity gap, particularly in underserved communities, and to save the planet from the devastating impacts of climate change.

Report Highlights

In its 2021 ESG Report, Moderna outlines its corporate responsibility strategy and defines five guiding focus areas for ongoing and future efforts:

  • Medicines for patients
  • Employees
  • Environment
  • Community
  • Governance and ethics

The report also includes updates to the progress Moderna has made to date:

  • 25% of total doses of its COVID-19 vaccine in 2021 were delivered to low- and middle-income countries.
  • 40% of Moderna’s U.S. workforce identifies as racially or ethnically diverse, up from 35% in 2020.
  • Moderna announced its Global Public Health Strategy to:
    • Advance vaccines targeting 15 pathogens identified as the biggest public health risks into clinical studies by 2025
    • Launch mRNA Access
    • Expand its COVID-19 patent pledge
    • Establish an mRNA Manufacturing Facility in Kenya, Africa
  • Moderna formed a new collaboration with the Institute for Life Changing Medicines to develop a new mRNA therapeutic (mRNA-3351) for Crigler-Najjar type 1 (CN-1), an ultra-rare disease. The goal of this partnership is to make an mRNA therapy for the treatment of CN-1 available at no cost to patients and their families.
  • Moderna affirmed its commitment to sustainability by pledging to achieve net-zero carbon emissions in by 2030. With its engineering and manufacturing teams, Moderna is designing the company roadmap to embed sustainability by design in its current facilities and future manufacturing sites.

To read more, please visit:

Media Contact:
Katherine O’Malley
Executive Director, Communications



In over 10 years since its inception, Moderna has transformed from a research-stage company advancing programs in the field of messenger RNA (mRNA), to an enterprise with a diverse clinical portfolio of vaccines and therapeutics across seven modalities, a broad intellectual property portfolio in areas including mRNA and lipid nanoparticle formulation, and an integrated manufacturing plant that allows for rapid clinical and commercial production at scale. Moderna maintains alliances with a broad range of domestic and overseas government and commercial collaborators, which has allowed for the pursuit of both groundbreaking science and rapid scaling of manufacturing. Most recently, Moderna's capabilities have come together to allow the authorized use and approval of one of the earliest and most effective vaccines against the COVID-19 pandemic. Moderna's mRNA platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, and has allowed the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases and auto-immune diseases. Moderna has been named a top biopharmaceutical employer by Science for the past seven years. To learn more, visit

Join today and get the latest delivered to your inbox